Targeting Staphylococci in Atopic Dermatitis

Inclusion Criteria: * • Male/Female subject from 18 years old or above. * Subject willing and able to fulfil the study requirements and schedule * Subject informed about the study objectives and procedures, and able to understand them * Subject who has given written informed consent * Subject with I, II, III or IV skin phototype * Specific criteria: For AD patients: * Subject diagnosed with AD (via UK working party criteria) with a mild-to-moderate severity defined as EASI\<32 and vIGA between 2 and 3 * Subject with at least one AD lesion covering at least 4 cm² For healthy volunteers: • Subject matching the demographic characteristics of a patient included in the AD group: same sex, same phototype, same age (± 5 years) Exclusion Criteria: * Subject with a body mass index (BMI) higher than 40 * Presenting another dermatological condition that could interfere with the clinical evaluation * Presenting any concomitant medical condition that may interfere with the study conduct in the opinion of the investigator * Topical or systemic treatment that could interfere with the study treatment/assessments (topical benzoyl peroxide, salicylic acid and other anti-acne or antiseborrheic products, antibiotics, corticosteroids, retinoids, differin gel, retin-A, anti-inflammatory drugs, within the 4 weeks prior to the participation in the study. * Any physical treatment including laser or phototherapy (PUVA, IPL, PDT), topical fillers such as Botox on the investigational sites in the last 6 months and during the study * Subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1 week before the inclusion visit or intending to be treated with it during the study. * Subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study. * Subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study. * Subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study. * Subject treated with systemic antibiotics within 2 weeks prior to the inclusion visit or planned during the study. * Subject having applied topical corticosteroids and topical calcineurin inhibitors on the investigational areas within 1 week prior to the inclusion visit. * Subject having applied topical immunomodulators, non-steroidal anti-inflammatory, antihistamines on investigational area within 1 week prior to the inclusion visit. * Subject having applied topical antibiotics or disinfectants on investigational area within 2 weeks prior to the inclusion visit. * Subject having applied any other topical and/or care product within 12 hours of the visit. * Subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit. * Subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark…) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations. * Subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study. * Subject having performed another physical treatment (e.g radiotherapy…) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study. * Subject having exposed their skin to natural or artificial UV within 2 weeks prior to the inclusion visit * Subject under legal guardianship or incapacitation. * Subject who declares to be deprived of freedom by administrative or legal decision * Subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment. * Subject who cannot be contacted by telephone in case of emergency. * Subject having participated within the 30 days before inclusion or currently participating in another clinical study.